New therapy strategies in secondary hyperparathyroidism on dialysis (I): New concepts. New treatments

J. Bover, F. Ortiz-Herbener, J. Ballarín, E. Andrés, P. Barceló

    Research output: Contribution to journalArticleResearchpeer-review

    5 Citations (Scopus)

    Abstract

    Secondary hyperparathyroidism (SHP) is still an early and frequent complication of chronic renal disease (CRD). Currently, CRD is an independent cardiovascular risk factor, and calcium-phosphorus metabolism is one of the modifiable related factors. In this first article, we summarize the recent SHP treatment paradigm shift in dialysis patients, derived from the better knowledge and understanding of vascular calcification. We analyze the most recent guidelines (K/DOQI), and describe the general implications of hyperphosphatemia, as well as our therapeutic approach with phosphorus-binders. Since sevelamer additionally presents some pleiotropic effects and it attenuates the progression of vascular calcification, we consider it in the first-line of treatment despite it is not yet demonstrated a survival benefit. We also minimize the use of elemental calcium to a maximum of 1,000 to 1,500 mg/day. Lanthanum carbonate may well be an important therapeutic agent in the near future, especially if security concerns related to metal accumu-lation are overcome. Ferric citrate, colestilan and nicotinamide may soon play a role. All these drugs, isolated or in combination, are important in the treatment of SHP since a great deal of its success and the avoidance of some dialysis-related complications depend on an efficient phosphorus control.
    Original languageEnglish
    Pages (from-to)100-108
    JournalNefrologia
    Volume25
    Issue numberSUPPL.2
    Publication statusPublished - 1 Jan 2005

    Keywords

    • Binders
    • Chronic renal disease
    • Dialysis
    • Lanthanum
    • Phosphate
    • Phosphorus
    • Secondary hyperparathyroidism
    • Sevelamer

    Fingerprint Dive into the research topics of 'New therapy strategies in secondary hyperparathyroidism on dialysis (I): New concepts. New treatments'. Together they form a unique fingerprint.

    Cite this